Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Agilon Health (AGL) EBIAT (2020 - 2025)

Agilon Health's EBIAT history spans 6 years, with the latest figure at -$188.9 million for Q4 2025.

  • For Q4 2025, EBIAT fell 78.54% year-over-year to -$188.9 million; the TTM value through Dec 2025 reached -$405.3 million, down 61.59%, while the annual FY2025 figure was -$405.3 million, 55.81% down from the prior year.
  • EBIAT reached -$188.9 million in Q4 2025 per AGL's latest filing, down from -$110.2 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $10.0 million in Q1 2023 to a low of -$298.9 million in Q2 2021.
  • Average EBIAT over 5 years is -$68.3 million, with a median of -$33.8 million recorded in 2021.
  • Peak YoY movement for EBIAT: crashed 8577.53% in 2021, then soared 761.56% in 2023.
  • A 5-year view of EBIAT shows it stood at -$56.7 million in 2021, then grew by 1.33% to -$56.0 million in 2022, then plummeted by 198.64% to -$167.1 million in 2023, then surged by 36.71% to -$105.8 million in 2024, then tumbled by 78.54% to -$188.9 million in 2025.
  • Per Business Quant, the three most recent readings for AGL's EBIAT are -$188.9 million (Q4 2025), -$110.2 million (Q3 2025), and -$104.4 million (Q2 2025).